Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.85 and traded as low as $0.80. Seres Therapeutics shares last traded at $0.84, with a volume of 446,477 shares changing hands.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the company. Canaccord Genuity Group reissued a "buy" rating and set a $10.00 price target on shares of Seres Therapeutics in a research report on Thursday, November 14th. Chardan Capital reissued a "buy" rating and set a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. StockNews.com raised Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday. Finally, JPMorgan Chase & Co. downgraded Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $5.08.
Get Our Latest Stock Report on Seres Therapeutics
Seres Therapeutics Stock Performance
The stock has a market capitalization of $142.18 million, a P/E ratio of -3.62 and a beta of 2.11. The stock has a 50 day moving average of $0.85 and a 200 day moving average of $0.86.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of MCRB. Vontobel Holding Ltd. bought a new position in shares of Seres Therapeutics in the third quarter worth $374,000. Charles Schwab Investment Management Inc. boosted its stake in Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company's stock valued at $708,000 after buying an additional 222,771 shares in the last quarter. FMR LLC boosted its stake in Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company's stock valued at $21,625,000 after buying an additional 140,096 shares in the last quarter. Providence Wealth Advisors LLC boosted its stake in Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock valued at $93,000 after buying an additional 22,250 shares in the last quarter. Finally, State Street Corp boosted its stake in Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after buying an additional 43,700 shares in the last quarter. Institutional investors own 59.34% of the company's stock.
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Further Reading
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
